Table 3 Comparison of the clinical characteristics between ampullary and non-ampullary duodenal NENs
From: Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs
Characteristics | Chinese patients | White patients | Black patients | ||||||
|---|---|---|---|---|---|---|---|---|---|
Ampullary NENs | Non-ampullary duodenal NENs | P | Ampullary NENs | Non-ampullary duodenal NENs | P | Ampullary NENs | Non-ampullary duodenal NENs | P | |
Age, years | Â | Â | 0.961 | Â | Â | 0.003 | Â | Â | 0.028 |
 Mean (95%CI) | 54.9 (51.9–58.0) | 54.8 (52.3–57.4) |  | 59.7 (57.1–62.3) | 63.6 (62.9–64.3) |  | 57.1 (52.5–61.7) | 63.0 (61.9–64.0) |  |
 Range | 25–81 | 17–80 |  | 31–87 | 13–97 |  | 34–80 | 21–94 | |
Sex | 72a | 122b | 0.337 | 117c | 1424d | 0.691 | 24e | 545f | 0.435 |
 Male | 35 (48.6%) | 68 (55.7%) |  | 60 (51.3%) | 703 (49.4%) |  | 13 (54.2%) | 251 (46.1%) |  |
 Female | 37 (51.4%) | 54 (44.3%) |  | 57 (48.7%) | 721 (50.6%) |  | 11 (45.8%) | 294 (53.9%) | |
Tumor size, cm | 61a | 93b | 0.010 | 86c | 851d | <0.001 | 21e | 312f | <0.001 |
 Median | 2.5 | 1.6 |  | 1.8 | 0.9 |  | 2.2 | 1.0 |  |
Presenting Symptoms | 72a | 122b | - | Â | Â | - | Â | Â | - |
 Abdominal pain | 34 (47.2%) | 63 (51.6%) |  |  |  |  |  |  |  |
 Jaundice | 26 (36.1%) | 7 (5.7%) | <0.001g |  |  |  |  |  | |
 Nausea/vomiting | 8 (11.1%) | 17 (13.9%) |  |  |  |  |  |  | |
 Bloating | 5 (6.9%) | 23 (18.9%) |  |  |  |  |  |  | |
 GI bleeding | 8 (11.1%) | 16 (13.1%) |  |  |  |  |  |  | |
 Diarrhea | 3 (4.2%) | 11 (9.0%) |  |  |  |  |  |  | |
 Intestinal obstruction | 4 (5.6%) | 3 (2.5%) |  |  |  |  |  |  | |
 Flushing | 2 (2.8%) | 2 (1.6%) |  |  |  |  |  |  | |
Incidental diagnosis | 72a | 122b | 0.386 | Â | Â | Â | Â | Â | Â |
 Yes | 8 (11.1%) | 19 (15.6%) |  |  |  |  |  |  |  |
 No (symptomatic) | 64 (88.9%) | 103 (84.4%) |  |  |  |  |  |  | |
Tumor grade | 63a | 112b | 0.003 | Â | Â | - | Â | Â | - |
 Grade 1 | 18 (28.6%) | 48 (42.9%) |  |  |  |  |  |  |  |
 Grade 2 | 15 (23.8%) | 39 (34.8%) |  |  |  |  |  |  |  |
 Grade 3 | 30 (47.6%) | 25 (22.3%) |  |  |  | <0.001 |  |  | 0.177 |
Tumor differentiation | Â | Â | - | 63c | 595d | Â | 15e | 209f | Â |
 Well differentiated |  |  |  | 28 (44.4%) | 469 (78.8%) |  | 10 (66.7%) | 161 (77.0%) | |
 Moderately differentiated |  |  |  | 12 (19.0%) | 86 (14.5%) |  | 3 (20.0%) | 40 (19.1%) | |
 Poorly or undifferentiated |  |  |  | 23 (36.5%) | 40 (6.7%) |  | 2 (13.3%) | 8 (3.8%) | |
T status | 60a | 95b | <0.001 | 78c | 812d | <0.001 | 19e | 281f | 0.002 |
 T1 | 4 (6.7%) | 29 (30.5%) |  | 15 (19.2%) | 482 (59.4%) |  | 3 (15.8%) | 162 (57.7%) |  |
 T2 | 20 (33.3%) | 39 (41.1%) |  | 39 (50.0%) | 240 (29.6%) |  | 13 (68.4%) | 96 (34.2%) | |
 T3 | 30 (50.0%) | 21 (22.1%) |  | 9 (11.5%) | 53 (6.5%) |  | 2 (10.5%) | 15 (5.3%) | |
 T4 | 6 (10.0%) | 6 (6.3%) |  | 15 (19.2%) | 37 (4.6%) |  | 1 (5.3%) | 8 (2.8%) | |
N status | 70a | 102b | 0.535 | 97c | 1235d | <0.001 | 22e | 457f | <0.001 |
 N0 | 47 (67.1%) | 73 (71.6%) |  | 51 (52.6%) | 1103 (89.3%) |  | 13 (59.1%) | 408 (89.3%) |  |
 N1 | 23 (32.9%) | 29 (28.4%) |  | 46 (47.4%) | 132 (10.7%) |  | 9 (40.9%) | 49 (10.7%) | |
M status | 72a | 122b | 0.071 | 110c | 1198d | <0.001 | 22e | 436f | 0.001 |
 M0 | 64 (88.9%) | 96 (78.7%) |  | 87 (79.1%) | 1130 (94.3%) |  | 17 (77.3%) | 417 (95.6%) |  |
 M1 | 8 (11.1%) | 26 (21.3%) |  | 23 (20.9%) | 68 (5.7%) |  | 5 (22.7%) | 19 (4.4%) | |
Tumor stage | 64a | 102b | <0.001 | 90c | 727d | <0.001 | 20e | 253f | 0.005 |
 I | 3 (4.7%) | 26 (25.5%) |  | 8 (8.9%) | 399 (54.9%) |  | 3 (15.0%) | 131 (51.8%) |  |
 II | 30 (46.9%) | 39 (38.2%) |  | 16 (17.8%) | 174 (23.9%) |  | 8 (40.0%) | 67 (26.5%) | |
 III | 23 (35.9%) | 11 (10.8%) |  | 43 (47.8%) | 86 (11.8%) |  | 4 (20.0%) | 36 (14.2%) | |
 IV | 8 (12.5%) | 26 (25.5%) |  | 23 (25.6%) | 68 (9.4%) |  | 5 (25.0%) | 19 (7.5%) | |